New Drug May Protect Gut From Antibiotic-Resistance Genes

MedicalResearch.com Interview with:

Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

Sheila Connelly, PhD
Vice President, Research
Synthetic Biologics, Inc.

MedicalResearch.com: What is the background for this study?

Response: Synthetic Biologics, Inc. is focused on the protection and preservation of the gut microbiome which is the diverse collection of microorganisms that live in the intestinal tract. We are learning that the gut microbiome plays a key role in health. Negative changes to the microbiome, called dysbiosis, are linked to disease states including allergies, autism, and obesity, among a rapidly growing list of other conditions. A consequence of using antibiotics is that, in addition to fighting the bacterial infection being treated, they also kill the gut microbiota. The space left in the gut by the dead bacteria allows other surviving bacteria, many times opportunistic pathogens or microbes that are resistant to multiple antibiotics, to overgrow and fill the open niches. Exposure to antibiotics, particularly broad-spectrum antimicrobials, such as penicillins and cephalosporins, is a major risk factor for acquiring a potentially deadly Clostridium difficile infection.

Dr-Sheila-Connelly.jpg

Dr. Sheila Connelly

Another consequence of antibiotic use is the emergence of antibiotic-resistant organisms. Widespread use of antibiotics provides selective pressure for the evolution of lethal, multi-drug resistant pathogens, termed “nightmare bacteria”. The gut microbiome acts as a reservoir of antibiotic resistance that can be triggered, by antibiotic exposure, to acquire and propagate resistance genes.

A way to protect the microbiome and reduce antibiotic resistance is to limit exposure of the gut microbiota to antibiotics. To this end, we developed an antibiotic inactivation strategy using a beta-lactamase enzyme to degrade beta-lactam antibiotics in the GI tract before they can harm the gut microbiome. Beta-lactamases are naturally-occurring bacterial enzymes that confer resistance to beta-lactams, the most widely used broad spectrum antibiotics, and their presence is normally considered an obstacle to efficacious infection control. We took advantage of the highly efficient antibiotic degradation activity of a beta-lactamase and developed SYN-004 (ribaxamase). Ribaxamase is a beta-lactamase engineered to inactivate penicillins and most cephalosporins, formulated for oral delivery, and intended for use with IV beta-lactam antibiotics to degrade the antibiotics in the GI tract to protect the microbiome.

Ribaxamase was demonstrated to significantly reduce the occurrence of C. difficile disease in a recently completed Phase 2b clinical study. The study met its primary endpoint by demonstrating that ribaxamase, when delivered orally with IV ceftriaxone, significantly reduced C. difficile disease in patients treated for a respiratory tract infection. Ribaxamase also resulted in a significant reduction in new colonization by vancomycin-resistant enterococcus (VRE).

For the current study, pig models of antibiotic-mediated gut dysbiosis were established using three classes of beta-lactam antibiotics, a cephalosporin, ceftriaxone, a penicillin, amoxicillin, and a carbapenem, ertapenem. The ceftriaxone model was used to evaluate the protective effect of ribaxamase on the microbiome and the amoxicillin and ertapenem models are intended for evaluation of pipeline products.

MedicalResearch.com: What are the main findings?

Response: Normal pigs were treated with IV ceftriaxone, oral amoxicillin, or IV ertapenem for seven days. One group of pigs received both oral ribaxamase and ceftriaxone. Whole genome shotgun sequence analyses of fecal DNA were performed to assess the effects of antibiotics on the gut microbiota and to measure antibiotic resistance genes as a gauge for the presence of antibiotic-resistant bacteria.

We found that all three antibiotics caused significant changes to the gut microbiome, including loss of some bacterial species and overgrowth of others. In contrast, animals treated with ribaxamase had microbiomes that were not significantly different from pre-treatment. Within four days of antibiotic exposure, a broad spectrum of resistance genes, including those conferring resistance to beta-lactam and non-beta-lactam antibiotics, was detected in the microbiomes. However, in the presence of ribaxamase, the frequency of antibiotic resistance genes was reduced.

Ribaxamase did not affect antibiotic blood levels in the pigs, a result similar to the clinical finding that ribaxamase did not interfere with antibiotic efficacy in treating the respiratory tract infection in patients.

Ribaxamase protected the gut microbiome from ceftriaxone-mediated damage and attenuated the emergence and propagation of antibiotic-resistance genes.

MedicalResearch.com: What should readers take away from your report?

Response: We established pig models of antibiotic-mediated microbiome disruption and tested antibiotic inactivation as a strategy to limit exposure of the gut microbiota to antibiotics. With ribaxamase, the gut microbiome was preserved and the emergence of antibiotic resistance was mitigated.

Not only did ribaxamase reduce the frequency of genes conferring resistance to ceftriaxone but also to a broad range of antibiotics. As many pathogens have acquired resistance to multiple antibiotics, ribaxamase could potentially reduce antibiotic resistance to many classes of antibiotics, not only the beta-lactams.

Ribaxamase is a first in class agent representing a new treatment paradigm, namely, protection of the microbiome by antibiotic inactivation without interfering with infection control.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: The pig models will be used to test pipeline products prior to advancing them into human clinical trials. The pig appears to be a relevant model of gut microbiome dysbiosis as the data obtained to date are similar to those gained from human trials. Pipeline products are intended to expand the utility of the antibiotic inactivation microbiome preservation strategy to include protection from oral beta-lactams and carbapenem antibiotics. We identified a novel carbapenemase and are currently formulating it for oral delivery. Similar to ribaxamase use with penicillins and most cephalosporins, oral delivery of a carbapenemase is intended to inactivate carbapenems in the GI tract to protect the microbiome and reduce the emergence of carbapenem-resistant bacteria. Notably, carbapenems are considered a “last resort” therapy and carbapenem-resistant enterobacteriaceae (CRE) are designated an “urgent threat” by the CDC. Strategies to reduce the evolution and propagation of CRE are needed immediately. 

MedicalResearch.com: Is there anything else you would like to add?

Response: Ribaxamase is intended for use with IV penicillins and most cephalosporins, but does not degrade all antibiotics, including carbapenems. The antibiotics ribaxamase does inactivate, such as piperacillin and ceftriaxone, are the most commonly used broad spectrum IV antibiotics, cause dysbiosis, and are risk factors for C. difficile disease. Importantly, recent data suggest that total antibiotic exposure is a key factor in secondary infection risk and in emergence of antibiotic resistance. Ribaxamase has the potential to lessen microbiome disruption by reducing cumulative antibiotic exposure in patients receiving multiple antibiotics.

An intact gut microbiome is important for maintenance of physical and mental health. Our goal is to reduce the risks of beta-lactam antibiotics by preserving the gut microbiome to prevent secondary infections and to attenuate the evolution of antibiotic resistance.

References:

Connelly, S, Furlan Freguia, C, Subramanian, P, Hasan, NA, Colwell, RR, and Kaleko, M. (2017). An Orally Delivered Beta-Lactamase Protects the Gut Microbiome from Antibiotic-Mediated Damage and Mitigates the Propagation of Antibiotic-Resistance Genes in a Porcine Dysbiosis Model. Presented at Digestive Disease Week, Abstract 332g; May 7, 2017, Chicago, Il.

Connelly, S, Bristol, JA, Hubert, S, Subramanian, P, Hasan, NA, Colwell, RR, and Kaleko, M. (2017). SYN-004 (ribaxamase), an Oral Beta-Lactamase, Mitigates Antibiotic-Mediated Dysbiosis in a Porcine Gut Microbiome Model. J Appl Microbiol in press.

Kaleko, M, Bristol, JA, Hubert, S, Parsley, T, Widmer, G, Tzipori, S, Subramanian, P, Hasan, NA, Koski, P, Kokai-Kun, J, Sliman, J, Jones, A, and Connelly, S. (2016). Development of SYN-004, an Oral Beta-Lactamase Treatment to Protect the Gut Microbiome from Antibiotic-Mediated Damage and Prevent Clostridium difficile Infection. Anaerobe, 41:58-67. 

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation:

DDW May  2017 abstract:

An Orally Delivered Beta-Lactamase Protects the Gut Microbiome from Antibiotic-Mediated Damage and Mitigates the Propagation of Antibiotic-Resistance Genes in a Porcine Dysbiosis Mode

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com

[wysija_form id=”5″]

 

 

 

Leave a Reply

Your email address will not be published.